Pharmacological characterization and neuroprotective efficacy of ZHB103, a novel long-acting rhKLK1.

Neurotherapeutics · 2026 · PMC12976534 · PMID 41547653

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Sanbexin (2 mg/kg) showed a trend toward reduction in cerebral infarct area compared with the model group, but the difference was not statistically significant.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.